Get started
Genmab A/SGenmab A/SGenmab A/S

Genmab A/S

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonalsETFs

GE9 chart


Full chart

GE9 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪15.24 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
13.5
Basic EPS (TTM)
18.5 EUR
Net income (FY)
‪1.05 B‬ EUR
Revenue (FY)
‪2.88 B‬ EUR
Shares float
‪58.46 M‬
Beta (1Y)
0.46

Employees


Employees (FY)
‪2.68 K‬
Change (1Y)
+478 +21.69%
Revenue / Employee (1Y)
‪1.07 M‬ EUR
Net income / Employee (1Y)
‪391.00 K‬ EUR

About Genmab A/S


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Jan G. J. van de Winkel
Website
genmab.com
Headquarters
Copenhagen
Founded
1998
ISIN
DK0010272202
FIGI
BBG000C5CP96
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Check out other big names from the same industry as GE9.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GE9 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where GE9 is featured.

See all sparks 

Frequently Asked Questions


The current price of GE9 is 246.7 EUR — it has decreased by −0.44% in the past 24 hours. Watch Genmab A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Genmab A/S stocks are traded under the ticker GE9.
GE9 stock has risen by 4.22% compared to the previous week, the month change is a 17.53% rise, over the last year Genmab A/S has showed a 14.00% increase.
We've gathered analysts' opinions on Genmab A/S future price: according to them, GE9 price has a max estimate of 394.51 EUR and a min estimate of 136.19 EUR. Watch GE9 chart and read a more detailed Genmab A/S stock forecast: see what analysts think of Genmab A/S and suggest that you do with its stocks.
GE9 reached its all-time high on Dec 12, 2022 with the price of 445.1 EUR, and its all-time low was 3.1 EUR and was reached on Nov 27, 2002. View more price dynamics on GE9 chart.
See other stocks reaching their highest and lowest prices.
GE9 stock is 1.43% volatile and has beta coefficient of 0.46. Track Genmab A/S stock price on the chart and check out the list of the most volatile stocks — is Genmab A/S there?
Today Genmab A/S has the market capitalization of ‪15.14 B‬, it has decreased by −2.88% over the last week.
Yes, you can track Genmab A/S financials in yearly and quarterly reports right on TradingView.
Genmab A/S is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
GE9 earnings for the last quarter are 4.60 EUR per share, whereas the estimation was 3.39 EUR resulting in a 35.74% surprise. The estimated earnings for the next quarter are 3.95 EUR per share. See more details about Genmab A/S earnings.
Genmab A/S revenue for the last quarter amounts to ‪785.24 M‬ EUR, despite the estimated figure of ‪767.63 M‬ EUR. In the next quarter, revenue is expected to reach ‪836.60 M‬ EUR.
GE9 net income for the last quarter is ‪295.57 M‬ EUR, while the quarter before that showed ‪185.12 M‬ EUR of net income which accounts for 59.67% change. Track more Genmab A/S financial stats to get the full picture.
No, GE9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 27, 2025, the company has ‪2.68 K‬ employees. See our rating of the largest employees — is Genmab A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Genmab A/S EBITDA is ‪1.13 B‬ EUR, and current EBITDA margin is 34.45%. See more stats in Genmab A/S financial statements.
Like other stocks, GE9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Genmab A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Genmab A/S technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Genmab A/S stock shows the buy signal. See more of Genmab A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.